Firemní tisková prohlášení

15 bře 2017

Patents licensed to Synthon relating to the CD47-SIRPα pathway resist challenges in the U.S. and Europe

read more
02 bře 2017

Synthon enters worldwide exclusive license and collaboration with Sanquin for immuno-oncology therapeutic leads modulating the CD47-SIRPα pathway

read more
12 pro 2016

MacroGenics Licenses Synthon’s Technology to Develop an Anti-B7-H3 ADC

read more
18 kvě 2016

Synthon advances clinical evaluation of anti-HER2 ADC SYD985 in an expanded cohort of HER2-positive metastatic breast cancer patients

read more
12 dub 2016

Synthon obtains approval for glatiramer acetate 20 mg/mL in Europe

read more
28 zář 2015

Synthon Reports Promising Initial Results from Phase I Trial with anti-HER2 ADC SYD985

read more
03 srp 2015

Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis

read more
28 dub 2015

Synthon Announces Successful Outcomes from the Open-label extension of the Phase III GATE Study of Synthon’s Glatiramer Acetate

read more
25 lis 2014

Synthon Initiates Treatment of First Patients in Phase I Trial of anti-HER2 ADC SYD985 based on its Proprietary Linker-Drug Platform

read more
09 říj 2014

Synthon Announces Filing of Glatiramer Acetate 40 mg/mL ANDA Containing a Paragraph IV Certification

read more